MannKind Announces Six-Month Results From Phase 3 INHALE-1 Pediatric Diabetes Trial Utilizing Inhaled Insulin (Afrezza®)
Company plans to meet with FDA regarding potential sNDA submission in 1H 2025Call planned today at 8:30 a.m. (ET) to discuss company’s diabetes ...
pharmaphorum10y
Inhaled insulin recommended by FDA committee
An FDA committee has given an overwhelming recommendation to new inhaled insulin treatment Afrezza. MannKind Corporation has spent years and many millions of dollars in developing the novel ...
MannKind reports six-month results from Phase 3 INHALE-1 trial
MannKind (MNKD) announced six-month results from its Phase 3 INHALE-1 study of Afrezza Inhalation Powder in children and adolescents. MannKind ...
The Korea Times7d
Inhalable insulin clears FDA
The U.S. Food and Drug Administration has approved inhalable insulin to help patients control their blood sugar levels. ManKind Corporation's Afrezza is a fast-acting form of insulin intended for ...
ThePrint on MSN3d
Cipla set to bring Afrezza, 1st inhalable insulin since Exubera, to Indian markets by 2025
Afrezza, world’s only rapid-acting, inhaled insulin for type 1 & type 2 diabetes patients & manufactured by MannKind, ...